Abstract
ABSTRACTBackgroundOpioids are strong pain medications that can be essential for acute pain. However, opioids are also commonly used for chronic conditions and illicitly where there are well recognised concerns about the balance of their benefits and harms. Technologies using artificial intelligence (AI) are being developed to examine and optimise the use of opioids. Yet, this research has not been synthesised to determine the types of AI models being developed and the application of these models.MethodsWe aimed to synthesise studies exploring the use of AI in people taking opioids. We searched three databases: the Cochrane Database of Systematic Reviews, EMBASE, and Medline on 4 January 2021. Studies were included if they were published after 2010, conducted in a real-life community setting involving humans, and used AI to understand opioid use. Data on the types and applications of AI models were extracted and descriptively analysed.ResultsEighty-one articles were included in our review, representing over 5.3 million participants and 14.6 million social media posts. Most (93%) studies were conducted in the USA. The types of AI technologies included natural language processing (46%) and a range of machine learning algorithms, the most common being random forest algorithms (36%). AI was predominately applied for the surveillance and monitoring of opioids (46%), followed by risk prediction (42%), pain management (10%), and patient support (2%). Few of the AI models were ready for adoption, with most (62%) being in preliminary stages.ConclusionsMany AI models are being developed and applied to understand opioid use. However, there is a need for these AI technologies to be externally validated and robustly evaluated to determine whether they can improve the use and safety of opioids.SUMMARY BOXKey PointsAcross the landscape of opioid research, natural language processing models (46%) and ensemble algorithms, particularly random forest algorithms (36%), were the most common types of AI technologies studied.There were four domains to which AI was applied to assess the use of opioids, including surveillance and monitoring (46%), risk prediction (42%), pain management (10%), and patient support (2%).The AI technologies were at various stages of development, validation, and deployment, with most (62%) models in preliminary stages, 11% required external validation, and few models were openly available to access (6%).
Publisher
Cold Spring Harbor Laboratory